File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Pathogenesis and treatment of leukemia: An Asian perspective

TitlePathogenesis and treatment of leukemia: An Asian perspective
Authors
Issue Date2012
PublisherInforma Healthcare. The Journal's web site is located at http://www.expertopin.com/loi/ett
Citation
Expert Opinion On Therapeutic Targets, 2012, v. 16 SUPPL. 1, p. S37-S43 How to Cite?
AbstractIntroduction: Leukemias occur worldwide, but there are important geographic differences in incidences. Areas covered: Three leukemias with special Asian perspectives, acute promyelocytic leukemia (APL), T-cell large granular lymphocyte (T-LGL) leukemia and NK-cell leukemia. Expert opinion: In APL, China has made contributions in discovering the efficacy of all-trans retinoic acid (ATRA) and arsenic trioxide. Some APL patients are potentially curable after treatment with ATRA or arsenic trioxide as a single agent. Combined treatment of APL with ATRA and arsenic trioxide induces remission with deeper molecular response. An oral formulation of arsenic trioxide is available, making outpatient treatment feasible. Future regimens for APL should examine how ATRA and arsenic trioxide can be optimally combined with other synergistic drugs. Asian patients with T-LGL leukemia present more frequently with pure red cell aplasia, but less frequently with neutropenia, recurrent infection, splenomegaly and rheumatoid arthritis as compared with Western patients. These differences have potential effects on treatment and disease pathogenesis. NK-cell leukemia is rapidly fatal and occurs almost exclusively in Asian and South American patients. Conventional anthracycline-based chemotherapy designed for B-cell lymphomas do not work in NK-cell leukemias. Novel therapeutic approaches targeting cellular signaling pathways or preferentially upregulated genes are needed to improve outcome. © 2012 Informa UK, Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/163463
ISSN
2015 Impact Factor: 4.798
2015 SCImago Journal Rankings: 2.025
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorKwong, YLen_US
dc.date.accessioned2012-09-05T05:31:42Z-
dc.date.available2012-09-05T05:31:42Z-
dc.date.issued2012en_US
dc.identifier.citationExpert Opinion On Therapeutic Targets, 2012, v. 16 SUPPL. 1, p. S37-S43en_US
dc.identifier.issn1472-8222en_US
dc.identifier.urihttp://hdl.handle.net/10722/163463-
dc.description.abstractIntroduction: Leukemias occur worldwide, but there are important geographic differences in incidences. Areas covered: Three leukemias with special Asian perspectives, acute promyelocytic leukemia (APL), T-cell large granular lymphocyte (T-LGL) leukemia and NK-cell leukemia. Expert opinion: In APL, China has made contributions in discovering the efficacy of all-trans retinoic acid (ATRA) and arsenic trioxide. Some APL patients are potentially curable after treatment with ATRA or arsenic trioxide as a single agent. Combined treatment of APL with ATRA and arsenic trioxide induces remission with deeper molecular response. An oral formulation of arsenic trioxide is available, making outpatient treatment feasible. Future regimens for APL should examine how ATRA and arsenic trioxide can be optimally combined with other synergistic drugs. Asian patients with T-LGL leukemia present more frequently with pure red cell aplasia, but less frequently with neutropenia, recurrent infection, splenomegaly and rheumatoid arthritis as compared with Western patients. These differences have potential effects on treatment and disease pathogenesis. NK-cell leukemia is rapidly fatal and occurs almost exclusively in Asian and South American patients. Conventional anthracycline-based chemotherapy designed for B-cell lymphomas do not work in NK-cell leukemias. Novel therapeutic approaches targeting cellular signaling pathways or preferentially upregulated genes are needed to improve outcome. © 2012 Informa UK, Ltd.en_US
dc.languageengen_US
dc.publisherInforma Healthcare. The Journal's web site is located at http://www.expertopin.com/loi/etten_US
dc.relation.ispartofExpert Opinion on Therapeutic Targetsen_US
dc.subject.meshArsenicals - Therapeutic Useen_US
dc.subject.meshAsian Continental Ancestry Groupen_US
dc.subject.meshCell Proliferationen_US
dc.subject.meshHumansen_US
dc.subject.meshLeukemia - Drug Therapy - Etiology - Pathologyen_US
dc.subject.meshLeukemia, Large Granular Lymphocytic - Drug Therapy - Etiologyen_US
dc.subject.meshLeukemia, Promyelocytic, Acute - Etiologyen_US
dc.subject.meshOxides - Therapeutic Useen_US
dc.subject.meshRecurrenceen_US
dc.subject.meshTretinoin - Therapeutic Useen_US
dc.titlePathogenesis and treatment of leukemia: An Asian perspectiveen_US
dc.typeArticleen_US
dc.identifier.emailKwong, YL:ylkwong@hku.hken_US
dc.identifier.authorityKwong, YL=rp00358en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1517/14728222.2011.621418en_US
dc.identifier.pmid22313234-
dc.identifier.scopuseid_2-s2.0-84857579198en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-84857579198&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume16en_US
dc.identifier.issueSUPPL. 1en_US
dc.identifier.spageS37en_US
dc.identifier.epageS43en_US
dc.identifier.isiWOS:000300712100007-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridKwong, YL=7102818954en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats